Sign in

    Keith J. Sullivan

    President and Chief Executive Officer at Neuronetics Inc
    Board
    Since March 7, 2024
    Age
    65 years
    Education
    Earned a Bachelor of Business Administration from the College of William and Mary.
    Tenure
    Has served as Director, President, and CEO of STIM since joining the company on July 14, 2020, with a promotion to the current CEO role on March 7, 2024.

    Also at Neuronetics Inc

    SF
    Stephen Furlong
    Executive Vice President, Chief Financial Officer, and Treasurer
    WAM
    W. Andrew Macan
    Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

    About

    Keith J. Sullivan is a seasoned executive in the medical device industry who currently leads STIM as its President and Chief Executive Officer. He assumed an influential leadership role at the company in mid-2020 and subsequently advanced to his current position, underscoring his commitment to driving the organization’s strategic vision.

    At 65 years old as of April 11, 2024, he brings over three decades of senior sales and leadership experience to the role. His personal and professional journey is marked by his extensive experience in the industry, contributing significantly to the growth and innovation within the healthcare technology sector.

    His career includes key roles at prominent companies, where he held positions such as Chief Commercial Officer and President (North America) at ZELTIQ Aesthetics, along with other senior leadership positions that helped shape his strategic outlook. In addition to his operational roles, he has been instrumental in major strategic initiatives at STIM, including driving expansion efforts that have led to substantial patient engagement and significant industry milestones.

    Beyond his executive responsibilities, he also serves on the Boards of Directors for other organizations, further highlighting his broad influence within the healthcare sector. His balanced approach in both leadership and strategic decision-making continues to contribute to his well-regarded professional legacy.

    $STIM Performance Under Keith J. Sullivan

    Past Roles

    OrganizationRoleDate RangeDetails
    ZELTIQ Aesthetics, Inc. Chief Commercial Officer and President (North America) January 2016 - April 2017 Developed products under the Coolsculpting® brand; acquired by Allergan, Inc. in April 2017
    ZELTIQ Aesthetics, Inc. Senior Vice President and Chief Commercial Officer November 2014 - January 2016 N/A
    ZELTIQ Aesthetics, Inc. Senior Vice President of Worldwide Sales and Marketing July 2013 - October 2014 N/A
    Medicis Pharmaceuticals Leadership Position N/A Specific title not provided
    Reliant Technologies Leadership Position N/A Specific title not provided
    Medtronic Leadership Position N/A Specific title not provided
    Vision Quest Laser Center Leadership Position N/A Specific title not provided
    Coherent Medical Leadership Position N/A Specific title not provided

    External Roles

    OrganizationRoleDate RangeDetails
    Sientra, Inc. Board of Directors N/A N/A
    Venus Concept Board of Directors N/A N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$700,000 Effective January 1, 2023; set on February 8, 2023 Determined by the Compensation Committee
    Restricted Stock Awards$1,601,700 (285,000 shares) Vests in 3 tranches: one-third at the 1st, 2nd, & 3rd anniversaries of the grant date (Feb 8, 2023) Grant date fair value calculated per ASC Topic 718
    Stock Options$0 N/ANo stock options awarded in 2023
    Other Compensation$28,485 Paid as incurred in 2023Includes automobile commuting costs ($14,929 with a $529 gross-up) and travel & entertainment expenses ($13,556 with a $3,301 gross-up)

    Performance Compensation

    Data from  FY 2023

    Annual Bonus Performance Compensation

    Metric/DetailValue/Description
    Performance MetricsCorporate revenue and EBIT objectives
    Target Opportunity100% of base salary ($700,000)
    Actual Payout94% of target, equaling $660,800
    Evaluation PeriodFiscal year 2023, evaluated in early 2024
    Thresholds/ConditionsBased on revenue, EBIT performance, market conditions, pilot program (Better Me Guarantee Provider) rollout, and achievement of positive Q4 cash flow
    Vesting ScheduleNot applicable (cash bonus)
    Additional DetailsPart of the 2023 annual non-equity incentive plan; bonus amount determined at the discretion of the Compensation Committee